SLXP up +0.96% percent Today $SLXP High is at 96.79 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 12:54 PM

SLXP up +0.96% percent Today $SLXP High is at 96.79 and the Low 95.25 with current volume of 671,701.

Recent News posted below.

Salix Pharmaceuticals SLXP other info.
http://investorshangout.com/Salix-Pharmaceuti...LXP-55453/

SLXP Salix Pharmaceuticals Recent Headline News

Robbins Arroyo LLP: Salix Pharmaceuticals, Ltd. (SLXP) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Wed Nov 12, 6:05PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between November 8, 2013 and November 6, 2014. Salix is a pharmaceutical company that focuses on treatments for digestive system diseases and disorders.
SLXP: 96.70 (+1.15)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Salix Pharmaceuticals Ltd and Certain Officers -- SLXP
GlobeNewswire - Wed Nov 12, 5:21PM CST
Pomerantz LLP has filed a class action lawsuit against Salix Pharmaceuticals Ltd ("Salix" or the "Company"

(Nasdaq:SLXP) and certain of its officers. The class action, filed in United States District Court, Eastern District of North Carolina, Western Division, and docketed under 14-cv-00804, is on behalf of a class consisting of all persons or entities who purchased Salix securities between August 7, 2014 and November 6, 2014, inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
SLXP: 96.70 (+1.15)

SHAREHOLDER ALERT: Investors of Salix Pharmaceuticals, Ltd. with Losses of $250,000 or More Are Encouraged to Contact Glancy Binkow & Goldberg LLP
Business Wire - Wed Nov 12, 11:32AM CST
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the "Class"

comprising purchasers of the securities of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"

(NASDAQ:SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period"

. Investors who have losses of $250,000 or more are encouraged to contact the firm for more information.
SLXP: 96.70 (+1.15)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Salix Pharmaceuticals Inc. (SLXP) To Contact The Firm
PR Newswire - Tue Nov 11, 4:23PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Salix Pharmaceuticals Inc. ("Salix" or the "Company"

(NASDAQ: SLXP) of the January 6, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Salix and certain executives.
SLXP: 96.70 (+1.15)

Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad Laboratories, Inc., Pingtan Marine Enterprise Ltd., Rayonier Inc. and Salix Pharmaceuticals, Ltd.
PR Newswire - Tue Nov 11, 11:10AM CST
Barrett Business Services, Inc.
RYN: 26.21 (+0.11), BIO: 112.15 (+0.22), BBSI: 21.80 (-0.99), SLXP: 96.70 (+1.15), PME: 1.36 (+0.06)

Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.78 (-0.11), AGN: 196.51 (unch), ACT: 241.70 (+1.08), VRX: 131.79 (+0.70), MDT: 69.35 (+0.85), SLXP: 96.70 (+1.15), SNY: 46.54 (-0.02)

Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 29.44 (+0.05), NVO: 44.01 (-0.31), AZN: 74.69 (+0.43), SLXP: 96.70 (+1.15), NVS: 94.44 (+1.78)

Hagens Berman Alerts Investors of Lead Plaintiff Deadline in Class Action Lawsuit Filed Against Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)
GlobeNewswire - Tue Nov 11, 7:38AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts investors that a class action lawsuit has been filed against Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix" or "the Company). The suit is pending in U.S. District Court for the Southern District of New York, and investors have until January 6, 2015 to move for lead plaintiff.
SLXP: 96.70 (+1.15)

Salix Pharmaceuticals: What Scares Me Most About Its High Inventory & Stock Collapse
Brian Nichols - at Seeking Alpha - Tue Nov 11, 6:50AM CST

SLXP: 96.70 (+1.15)

SALIX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Salix Pharmaceuticals Ltd. - SLXP
GlobeNewswire - Mon Nov 10, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF"

and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 6, 2015 to file lead plaintiff applications in a securities class action lawsuit against Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) if they purchased the Company's securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period"

. This action is pending in the United States District Court for the Southern District of New York.
SLXP: 96.70 (+1.15)

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals, Ltd.
Business Wire - Mon Nov 10, 3:28PM CST
Rigrodsky & Long, P.A.:
SLXP: 96.70 (+1.15)

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
GlobeNewswire - Mon Nov 10, 3:11PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"

(Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014.
SLXP: 96.70 (+1.15)

Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 196.49 (-0.02), VRX: 131.79 (+0.70), AUXL: 32.51 (-0.01), SLXP: 96.70 (+1.15)

Wolf Popper LLP Announces Investigation on Behalf of Investors in Salix Pharmaceuticals Ltd.
PR Newswire - Mon Nov 10, 11:09AM CST
Wolf Popper LLP is investigating potential claims on behalf of investors in Salix Pharmaceuticals Ltd. ("Salix"

common stock (NASDAQ: SLXP) during the period May 10, 2013 through November 6, 2014, concerning possible violations of federal securities laws. Such investors are advised to contact Fei-Lu Qian at 877.370.7703 or fqian@wolfpopper.com.
SLXP: 96.70 (+1.15)

Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals Ltd. -- SLXP
GlobeNewswire - Mon Nov 10, 10:40AM CST
Morgan & Morgan announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals Ltd. ("Salix" or the "Company"

(Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period"

.
SLXP: 96.70 (+1.15)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 173.20 (-0.48), SLXP: 96.70 (+1.15), ICPT: 160.38 (-2.58), IBB: 295.54 (-0.95), AGIO: 86.76 (-0.11)

Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Nov 10, 8:51AM CST
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a "dead cat bounce" (down big yesterday but up big today) candidate
SLXP: 96.70 (+1.15)

Salix Pharmaceuticals (SLXP) Downgraded From Buy to Hold
at The Street - Mon Nov 10, 8:35AM CST
Salix Pharmaceuticals SLXP has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+. TheStreet Ratings Team has this to say about their recommendation:
SLXP: 96.70 (+1.15)

Deadline in Lawsuit for Investors in Salix Pharmaceuticals, Ltd. (SLXP) Shares Announced by Shareholders Foundation
GlobeNewswire - Mon Nov 10, 8:30AM CST
The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers of shares of Salix Pharmaceuticals, Ltd. (SLXP) over alleged Federal Securities Laws Violations by Salix Pharmaceuticals, Ltd.
SLXP: 96.70 (+1.15)

Downgrade Alert for Salix Pharmaceuticals (SLXP)
Comtex SmarTrend(R) - Mon Nov 10, 8:04AM CST
Salix Pharmaceuticals (NASDAQ:SLXP) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $91.47 on volume of 25.8 million shares, above average daily volume of 2.0 million. In the past 52 weeks, shares of Salix Pharmaceuticals have traded between a low of $82.52 and a high of $172.98 and closed yesterday at $91.47, which is 11% above that low price. The 200-day and 50-day moving averages have moved 0.63% higher and 1.83% lower over the past week, respectively.
SLXP: 96.70 (+1.15)

Salix Pharmaceuticals Ltd. (SLXP) Stock Research Links

SLXP Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEVEX Faces $100K+ Losses in New Investor Lawsuit

When the suits start flying, folks, you know there's a mess brewing somewhere in the market. Here we are, talking about AEVEX Corp, ticker NYSE:AVEX, and they’re facing some serious heat. There's some scuttlebutt about a class action lawsuit that’s got investors clutching onto their wallets tighter than ever. If you’ve been scouring over the papers, this lawsuit is...

Tetragon Completes $50M Tender Offer; Shares Prorated

Unpacking Tetragon’s $50 Million Dutch Auction Move If you comb through the smoke-filled corridors of finance, you'll find the name Tetragon Financial Group pacing the latest tender offer rounds. They danced their way through a $50 million 'modified Dutch auction,' snapping up non-voting shares with a kind of ruthless efficiency that only seasoned market players can...

Solomon e3 Halves Cloud Costs with NexQloud Shift

Ever feel like you're drowning in an unnecessary cloud bill? Well, Solomon e3 did something about it. They chopped over half of their cloud spending after partnering with NexQloud. This isn't just an old-school belt-tightening; it's a full-on digital revamp after a deep-dive into their IT finances. Saving Pennies and Dollars with Smart Moves You'd think an energy company...

Virterion Surges Ahead in VPS Racing With Reliable Hosting

Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...

CRESYN Opens Model Residence: A Peek at City Living

CRESYN: Urban Elegance Hits Long Island City Who doesn't want to peek under the hood when a flashy new ride rolls into town? CRESYN's newly unveiled model residence in Long Island City is just that—an invitation to get up close and personal with what modern urban living can be. Forget the blueprints and glossy renderings. This place is the real deal, giving you that...

Agroz: Awards Fuel Momentum in AgriTech Sphere

Agroz Surging Ahead with Global Acclaim There's a new breeze blowing through the AgTech industry, and it's carrying Agroz Inc. (NASDAQ: AGRZ) straight to the top. Fresh off the back of snagging several prestigious international awards, this vertically integrated agricultural tech powerhouse is making waves not just in Malaysia, but on the global stage. Top of the FoodTech...

Western Computer Reaps Microsoft AI Honor: Impact & Insights

Western Computer Racks Up Another Microsoft Gong Alright, put down your coffee and listen up. When a company like Western Computer snags recognition from Microsoft a third time, they're not just ringing their own bell—they're practically sounding a bugle. Microsoft threw them into their AI Business Solutions Inner Circle for 2026/2027. That’s the gold club membership...

ASU Teams Up for National Manufacturing Workforce Push

ASU's Role in Reviving American Manufacturing The Foundry School is a big hit for Arizona State University (ASU) as it joins hands with seven other top-tier universities under the U.S. Departments of State and Labor's initiative. This project is all about sculpting the future players of American manufacturing. In a scene highlighted by the Vice President and girded by...

Crossware Joins Ingram Micro Platform for Wider Reach

Email Signature Game Changer Taps New Markets What goes around comes around, they say. Well, in the email signature business, it seems Crossware is putting that old adage to bed by building a highway straight through Ingram Micro's Xvantage platform. Yep, Crossware's shaking hands with Ingram to spread its email signature prowess to even more necks of the woods,...

GoDaddy Faces Class Action: Investor Stakes High

GoDaddy's Legal Turbulence: What's at Stake? Sometimes riding the stock wave can hit unexpected snags, and that's what's up with GoDaddy right now. They're stuck in the middle of a securities deception storm that's sending shivers down the spine of many an investor. The Class Action Lawsuit's Core Here's what you need to know: GoDaddy, with its ticker NYSE:GDDY, is...